Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm to Present Clinical Data at COSA 2018 Annual Meeting

• Clinical Oncology Society of Australia

• Provides updates on CEP-1 and DARRT-1 clinical studies

• Confirms tolerability of Veyonda

• Evidence of durable halt of tumour progression in both studies

SYDNEY,November 13, 2018, Noxopharm (ASX:NOX) announces that it is presenting two posters at the 45th Annual Meeting of the Clinical Oncology Society of Australia (COSA) which is being held November 13-15 in Perth, Australia.


For further information please download PDF attached:
Download this document